

Biopharmaceutical affinity profiling of antibody and antibodydrug-conjugate preparations by on-line post-column surface plasmon resonance biosensing & mass spectrometry



Jeroen Kool

Division of BioAnalytical Chemistry Group of BioMolecular analysis VU University Amsterdam, The Netherlands



CASSS AT Europe 2020 online in 'Lisbon' November 2020

Surface Plasmon Resonance



Biopharmaceuticals and their breakdown products

Biopharmaceuticals can degrade under various conditions such as heat, oxidation and/or long term storage

Biopharmaceuticals can differ from batch to batch during the production process

Upon entering the body, biopharmaceuticals are metabolized, degraded and digested by the body

Biopharmaceutical antibodies are always mixtures; i.e. 'biopharmaceutical preparations'

So we are looking at mixture analysis



LC-SPR Hyphenation

Biopharmaceutical breakdown products



TRASTUZUMAB AS BIOPHARMACEUTICAL EXAMPLE

- > 20,000 HER2 receptors are typically expressed on the surface of healthy cell
- Cancer cell: HER2 proteins are over expressed, 2 million receptors on the tumor cell surface





TRASTUZUMAB AS BIOPHARMACEUTICAL EXAMPLE

Drug development



AFFINITY DETERMINATION - SIZE VARIANTS

Size Exclusion Chromatography (SEC)



SEC-SPR ANALYSIS, STRESSED SAMPLES



LC-SPR-MS





LC-SPR-MS - RESULTS



Acknowledgements

Biomolecular Analysis; VU

- Dina Lakayan
- Rob Haselberg
- Govert Somsen
- Wilfried Niessen
- Fine Mechanical and Electronic Workshops; VU
 - Dick van Iperen
 - Rob Limburg

• BioNavis

- Jussi Tappurainen
- Niko Granqvist



